Dr. Jasdave S. Chahal, Chief Scientist at Tiba Biotech, holds a B.Sc. with honors in Biopharmaceutical Science from the University of Ottawa, and a Ph.D. in molecular biology from Princeton University. He began his postdoctoral research in 2013 with Dr. Hidde Ploegh at the Whitehead Institute to focus on vaccinology and immunotherapy, initiating projects to engineer RNA molecules as vectors against infectious disease and cancer. His published work demonstrated the effectiveness of these synthetic RNA payloads delivered with dendritic nanomaterials against viral and complex parasitic diseases in animal models. He transitioned to the Massachusetts Institute of Technology’s Koch Institute for Integrative Cancer Research in 2016 to further refine the technology before co-founding Tiba Biotech. Jasdave leads R&D activities at the company, advancing a range of academic and government collaborations.